The Pharma Data

DECEMBER 21, 2020

(Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. It is in advanced development for the treatment of Marburg virus disease.

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

The Pharma Data

JANUARY 19, 2021

A range of companies are exploring potential gene editing therapies based on a CRISPR-Cas9 system, and the ability to tune the CRISPR cut could prevent off-target editing or control the degree of a target protein’s production. The authors found that tracr-L redirects Cas9 in S. The authors suggest natural tracr-L regulates autoimmunity.

Research 52

Research RNA Molecular Biology Small Molecule 52

Drug Target Review

SEPTEMBER 28, 2023

After some time in that role and launching several products, I received a call from Bill Banyai and Bill Peck, or ‘The Bills’ as we call them, who were building a company around technology that creates DNA by ‘writing’ it on a silicon chip. These are synthetic, not the live virus, so do not pose a risk of infection.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

OCTOBER 19, 2020

Spectrum’s self-contained saliva collection kit provides critical sample consistency while suspending and neutralizing viral RNA transcripts completely inactivating the live virus. Qualified commercial RNA extraction chemistries include Perkin Elmer, Thermo Fisher, Roche, and Qiagen. This press release features multimedia.

RNA 52

RNA DNA Engineering Virus 52

The Pharma Data

JANUARY 11, 2021

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. based company has been in business for 10 years, but the COVID-19 vaccine was its first approved product. 18, 2020 ). The Cambridge, Mass.-based

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

The Pharma Data

DECEMBER 3, 2020

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. Trimer-Tag © is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JANUARY 31, 2021

Clover expects to produce hundreds of millions of vaccine doses in 2021 and up to 1 billion vaccine doses in peak annual production as required by global demand. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

DrugBank

JANUARY 29, 2025

In sickle cell disease, for instance, a missense mutation in the HBB gene , encoding the beta-globin subunit of hemoglobin, leads to the production of abnormal hemoglobin S. Gene therapy strategies targeting oncogene inactivation, such as RNA interference and gene-editing technologies, have shown promise in preclinical and clinical studies.

Therapies 52

Therapies DNA RNA Disease 52

New Drug Approvals

SEPTEMBER 6, 2024

TLR7-9 are among the set that are endosomally located and respond to single-stranded RNA (TLR7and TLR8) or unmethylated single-stranded DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9). Toll/IL-1 receptor family members are important regulators of inflammation and host resistance. Nature Immunol., 11:373-384 (2010)).

RNA 62

RNA Clinical Trials Disease DNA 62

The Pharma Data

JANUARY 21, 2021

Cabotegravir is a ViiV product marketed as Cabenuva, and rilpivirine is a Janssen product with a brand name Edurant. While much more remains to be done to make HIV history, today’s milestone reminds us how far medical innovation has come since the first reported cases of the virus almost 40 years ago.”. Most Read Today.

FDA Approval 52

FDA Approval Treatment FDA Clinical Trials 52

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Licensing 52

Licensing Licensing Therapies Disease 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

NOVEMBER 5, 2020

5 of its ongoing Phase 2 extension study, Study 211, examining vebicorvir (VBR, or ABI-H0731) in patients with hepatitis B virus infection. We maintain this can best be accomplished through a combination of agents with different mechanisms of action that target distinct parts of the virus lifecycle. Assembly Biosciences, Inc.

Virus 40

Virus Clinical Trials Therapies Pharmacokinetics 40

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 6, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union. About Moderna.

Vaccine 52

Vaccine RNA FDA Clinical Trials 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

SEPTEMBER 1, 2020

This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes. Roche is working closely with governments and health authorities around the world, and has significantly increased production to help ensure availability of tests globally.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

The Pharma Data

JANUARY 12, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland. .–(BUSINESS WIRE)–Jan. 12, 2021– Moderna, Inc. About Moderna.

Vaccine 52

Vaccine RNA Clinical Trials Science 52

The Pharma Data

JUNE 25, 2021

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. “We remain focused on being proactive as the virus evolves by leveraging the flexibility of our mRNA platform to stay ahead of emerging variants.” Moderna, Inc., This purchase brings the U.S.

Government 40

Government Vaccine RNA Science 40

Codon

JUNE 11, 2024

Their solution was to fuse hairpins, little loops made from RNA or DNA, at various positions along the DNA strand that was being sequenced. A partial solution to the problem came in 2005 when a team of researchers at the Scripps Institute found a “hacky” way to slow down the speed of nucleotides.

DNA 93

DNA Engineering RNA Small Molecule 93

The Pharma Data

DECEMBER 3, 2020

The FDA has scheduled an advisory committee meeting for next week, December 8, 9 and 10, for the Pfizer-BioNTech product and potentially could grant approval on December 10, or within a few days afterward. On Tuesday, the Pfizer-BioNTech vaccine was granted temporary authorization in the UK and dosing will begin next week.

Vaccine 52

Vaccine Government RNA FDA 52

The Pharma Data

MARCH 11, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 13, 2021

.” The Johnson & Johnson vaccine also would be hardier than either of the already approved vaccines because it relies on DNA technology rather than messenger RNA to prompt an immune system response. However, federal officials have been told the company is as far as two months behind its original production schedule, the Times added.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

OCTOBER 21, 2020

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency’s (EMA) recently issued a positive opinion recommending marketing authorisation for long-acting cabotegravir and rilpivirine in both injectable and tablet formulations. About ViiV Healthcare.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

New Drug Approvals

SEPTEMBER 7, 2024

Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses. The genomic RNA of CoVs has a 5′-cap structure and 3′-poly-A tail and contains at least 6 open reading frames (ORFs). μM and <0.1mM for 229E hCoV and SARS-CoV-23C-like (3CL) proteases , respectively. Zevotrelvir has the potential to study viral infections.

RNA 62

RNA Virus Therapies Pharmaceuticals 62

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Healthcare workers have been on the front lines of the fight against the virus and are an inspiration to us all. 20, 2020 02:44 UTC. CAMBRIDGE, Mass.–( –( BUSINESS WIRE )– Moderna, Inc.,

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

NOVEMBER 16, 2020

Since early January, we have chased this virus with the intent to protect as many people around the world as possible. I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, and the staff at our clinical trial sites who have been on the front lines of the fight against the virus. CAMBRIDGE, Mass.–(BUSINESS

Vaccine 52

Vaccine Clinical Trials FDA Disease 52

The Pharma Data

JANUARY 21, 2021

Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. 50 c/mL, meeting noninferiority criteria.

FDA Approval 52

FDA Approval Treatment RNA FDA 52

Codon

JUNE 25, 2024

During my doctoral training, I split my work between wet lab research and programming, two streams that differed radically in terms of productivity. In contrast, coding errors, while expected, disrupt productivity far less—so much so that programmers joke that “code never works the first time around.”

DNA 90

DNA RNA Laboratories Research 90

PLOS: DNA Science

JUNE 13, 2024

The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. Her points: 1. Coincidence? I’ve never thought so. RaTG13 shares about 96.1%

Virus 52

Virus RNA DNA Science 52

Drug Target Review

SEPTEMBER 4, 2023

Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. Studies have shown that targeting some expression gene sites could lead to the production of new drugs as indicated. They could be spread by physical contact, airborne, waterborne, foodborne, or vector-borne.

Drugs 111

Drugs RNA DNA Disease 111

Drug Target Review

OCTOBER 2, 2024

RNA-based therapies, including mRNA and RNA interference (RNAi), are being explored to modulate gene expression in heart cells. For instance, mRNA therapies can promote the production of specific proteins required for heart tissue repair, while RNAi can silence harmful gene expression, such as those driving fibrosis in heart failure.

Therapies 98

Therapies Disease Engineering RNA 98

Codon

MARCH 20, 2023

Basic Science A trailing ribosome speeds up RNA polymerase at the expense of transcript fidelity via force and allostery. Point-of-care peptide hormone production enabled by cell-free protein synthesis. Ribozyme-mediated RNA synthesis and replication in a model Hadean microenvironment. Signal Transduction and Targeted Therapy.

Virus 52

Virus Engineering RNA Small Molecule 52

New Drug Approvals

AUGUST 22, 2023

1951476-79-1 Hepatitis B virus (HBV) is an infectious disease that targets the liver resulting in either an acute infection, with symptoms arising in 45 to 160 days, or a chronic infection, which 350 million people worldwide are affected by. None of the solvents tested worked and all conditions produced an oil product.

RNA 52

RNA DNA Virus Treatment 52

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., For more information about Atea and our pipeline of product candidates please visit our company website at www.ateapharma.com.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52